EUIPO sides with Takeda in trademark appeal

Japan-based Takeda Pharmaceutical has persuaded the European Union Intellectual Property Office (EUIPO) that an applied-for trademark would be confused with its own earlier-registered mark.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Takeda ‘to sell OTC business in Europe’ to fund Shire acquisition

31 October 2018 Japan-based Takeda Pharmaceuticals is reportedly planning to sell its European over-the-counter business to lessen its debt from acquiring biotech company Shire.

Generics

Class-action accuses Takeda of ‘pay-for-delay’ deal with Par

1 July 2021 Takeda Pharmaceuticals organised a pay-for-delay deal with Par Pharmaceuticals to prevent a generic version of its constipation treatment from releasing, according to a complaint submitted to the US District Court for the District of Massachusetts.

More on this story

Big Pharma

Takeda ‘to sell OTC business in Europe’ to fund Shire acquisition

31 October 2018 Japan-based Takeda Pharmaceuticals is reportedly planning to sell its European over-the-counter business to lessen its debt from acquiring biotech company Shire.

Generics

Class-action accuses Takeda of ‘pay-for-delay’ deal with Par

More on this story

Big Pharma

Takeda ‘to sell OTC business in Europe’ to fund Shire acquisition

31 October 2018 Japan-based Takeda Pharmaceuticals is reportedly planning to sell its European over-the-counter business to lessen its debt from acquiring biotech company Shire.

Generics

Class-action accuses Takeda of ‘pay-for-delay’ deal with Par